Scientific in Medical Technology

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

NEW ORLEANS and CARLSBAD, Calif., June 9 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Isis' antisense drugs were highlighted with eight presentations (including three oral talks and two late-breaking posters) during the American Diabetes Association's...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today presented results from a pre-clinica...

SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine

WASHINGTON, June 7 /PRNewswire/ -- BARI-2D is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options. The Society for Cardiovascular Angiog...

Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions

- Late-Breaking Abstract Accepted - SAN DIEGO, June 1, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that a late-breaking abstract of its lorcaserin Phase 3 BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) tr...

Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial

Risk of death at five years is lower for aneurysm patients treated with coil embolization compared to surgical clipping NATICK, Mass., May 26 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed publication of results from the ISAT clinical trial in The Lancet...

Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease

NATICK, Mass., May 20 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the start of patient enrollment in the ORION clinical trial, which is designed to evaluate the Company's EPIC(TM) Self-Expanding Nitinol Stent System for the treatment of iliac artery disea...

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

TAXUS(R) Element(TM) Stent now available in select markets worldwide NATICK, Mass., May 19 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the launch of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets...

Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials

NATICK, Mass., May 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced data from its ALTITUDE Clinical Science program that show real-word survival rates for implantable cardiac device patients exceeding rates from clinical trials. ALTITUDE analyzes outcomes ...

Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine

Data from landmark trial provide important insight for physicians in treating heart attack patients NATICK, Mass., May 6 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed the publication of results from the HORIZONS AMI trial in this week's issue of the New...

Results From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session

SAN MATEO¿ Calif.¿ March 23 /PRNewswire/ -- Results from the Phase II portion of a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented at 10:30 a.m. EDT on Sunday, March 29, at the American College of Cardiology's (ACC...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

Journal of American College of Cardiology publishes positive ATLAS clinical data NATICK, Mass., Feb. 5 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the final modules of the Company's...

Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent

PLATINUM clinical program to evaluate PROMUS(TM) Element(TM) Platinum Chromium Stent NATICK, Mass., Feb. 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the beginning of patient enrollment in the PLATINUM clinical trial, which is designed to evaluate t...

Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions

Phase 1 Data Demonstrate Safety and Improvement in Heart Failure in a Majority of Patients NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced today results from the first nine patients treated with MYDICAR(R), a genetically-targeted enzyme replacement ...

Portola Announces Data Presentations Relevant to Its Lead Phase II Antithrombotic Compounds at American Heart Association Scientific Sessions 2008

SOUTH SAN FRANCISCO, Calif., Nov. 6 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, today announced that data relevant to betrixaban, the company's novel ...

Cytopia Scientific Presentations on JAK2 Inhibitor Program

MELBOURNE, Australia, Oct. 16 /PRNewswire/ -- Cytopia Limited (ASX: CYT) will present data on its JAK2 inhibitor program at two important scientific meetings this month. Dr Emmanuelle Fantino, Head of Biology at Cytopia, will present a lecture entitled Targeted JAK2 Inhibitors for Myeloproli...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

NATICK, Mass., Oct. 10 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) twentieth annual Transcatheter Cardiovascular Therapeutics (TCT) sci...

Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent

PERSEUS clinical program to evaluate TAXUS(R) Element(TM) Platinum Chromium Stent NATICK, Mass., Oct. 8 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced that it has completed enrollment in the PERSEUS trial, designed to evaluat...

Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting

SAN DIEGO, Oct. 7 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical company, today announced findings from its development of PROMETHEUS(R) IBS Diagnostic, the first and only blood test for irritable bowel syndrome (IBS). The findings suggest measurable differences in th...

Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting

Study Showed Larazotide Acetate Prevented Immunologic Changes Induced by Gluten in Patients with Celiac Disease Additional Data Indicates Potential in Treating Inflammatory Bowel Disease ORLANDO, Fla., Oct. 7 /PRNewswire/ -- Alba Therapeutics Corporation presented results from...

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

Data support the therapeutic potential of Amylin's integrated neurohormonal approach to obesity pharmacotherapy SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today announced that new data for its pipeline obesity candidates will be pre...

American Heart Association Scientific Statement: Heart Patients Should Be Screened, Treated for Depression

Studies show that depression is about three times more common in patients following a heart attack than in the general community. Heart patients should be screened for depression, and treated if necessary. DALLAS, Sept. 30 /PRNewswire-USNewswire/ -- Heart patients should be screened for de...

Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval

SAN MATEO, Calif., Sept. 24 /PRNewswire/ -- Anthera Pharmaceuticals announced today they have reached agreement with the U.S. Food and Drug Administration (FDA) on a Phase 3 protocol for varespladib (A-002) in acute coronary syndrome (ACS) under the FDA's Special Protocol Assessment procedure....

Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference

- Comprehensive Phase 3 Clinical Program Initiated - CAMBRIDGE, Mass. and NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals (formerly Microbia) and Forest Laboratories, Inc. (NYSE: FRX ) today announced they will present results of a Phase 2b study investigating ...

Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America

CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) announced it presented results from a Phase 1 clinical study with PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of the chronic treatment of ...

VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008

Topline Data from Phase 2 CEA and ACS Clinical Trials to be Released Concurrent with AHA Presentation SAN FRANCISCO, Sept. 15 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), a biotechnology company focused on the development of compounds for the treat...

Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting

SAN DIEGO, Sept. 9 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ) today announced that preclinical data will be presented on the Company's lead mitogen-activated ERK kinase (MEK) inhibitor, RDEA119, at the American College of Gastroenterology Annual Scientific Meeting at th...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008

Company to present data from landmark SYNTAX clinical trial NATICK, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced the schedule of the Company's major events and press announcements at the European Society of Cardiology Congress 2008,...

Seventy Years Old and Going Strong With Down Syndrome and No Dementia: The Case of 'Mr. C' Causes Major Interest in the Scientific Community

Study findings offer hope for increased life expectancy for people with Down syndrome WASHINGTON, Aug. 18 /PRNewswire-USNewswire/ -- In the world of Down syndrome, 'Mr. C' is a rarity. A real person whose progress has been tracked for the past 16 years, at seventy, 'Mr. C' has well surpassed...

Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences

NEW HAVEN, Conn., Aug. 5 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, announced today that company representatives are givi...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

Company's End-of-Phase II Meeting with FDA Set for Sept. 29 LA JOLLA, Calif., June 30 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today announced that data presented at the 50th Annual Scientific Meeting of the American Headache Society showed that, in addition to mee...

Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting

MOUNTAIN VIEW, Calif., June 23 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that it will present results of its Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) for the treatment of migraine headache at the 50th Annual Scientific Meeting of th...

Seven Presentations by Two Independent Research Groups Highlight Advantages of Pressure Cycling Technology (PCT) at Scientific Symposia in Philadelphia, Boston, and New York City

SOUTH EASTON, Mass., May 21 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI") today announced that scientists from the New York University (NYU) School of Medicine, the Brooklyn Hospital Center, and the Harvard School of Public Health made presentations highlighting...

SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents

NATICK, Mass. and BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today welcomed two-year results from the SPIRIT III clinical trial, which continue to reaffirm the proven long-term safety and efficacy of the market-leading TAXUS(R) Express2(TM) P...

Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists

VYVANSE demonstrated significant improvement in ADHD symptoms in adults WASHINGTON, May 8 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated signif...

Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session

TAMPA, Fla., May 8 /PRNewswire-FirstCall/ -- Alpharma Inc. (NYSE: ALO ), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated ...

Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting

PHILADELPHIA, May 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphen...

Clinical Impact of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology

HONG KONG, May 1 /PRNewswire/ -- The clinical impact of the first-ever pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, is the subject of a symposium at next month's 16th Annual Scientific Congress of the Hong Kong College of Cardiology. Scheduled for May 3 at the Sheraton Hong...

Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings

SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR ) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetings over the coming months. These presentations will highlig...

Arpida Invited to Present Data on Iclaprim at Scientific Conference

REINACH, Switzerland, April 9 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) announced today that a total of 13 abstracts on iclaprim have been accepted for the upcoming 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) which takes place in Barcelona, 19-22 Ap...

Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium

WALTHAM, Mass., April 3, 2008 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO ), the world leader in serving science, announced that it has received U.S. Food and Drug Administration (FDA) clearance for Spectra(TM) MRSA, a test designed to screen for methicillin-resistant S...